Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma

Belantamab mafodotin, a monomethyl auristatin F (MMAF)–containing monoclonal antibody‐drug conjugate (ADC), demonstrated deep and durable responses in the DRiving Excellence in Approaches to Multiple Myeloma (DREAMM)‐1 and pivotal DREAMM‐2 studies in patients with relapsed/refractory multiple myelom...

Descripción completa

Detalles Bibliográficos
Autores principales: Collins, Jon, van Noort, Martijn, Rathi, Chetan, Post, Teun M., Struemper, Herbert, Jewell, Roxanne C., Ferron‐Brady, Geraldine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583243/
https://www.ncbi.nlm.nih.gov/pubmed/37465991
http://dx.doi.org/10.1002/psp4.13016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583243/
https://www.ncbi.nlm.nih.gov/pubmed/37465991
http://dx.doi.org/10.1002/psp4.13016

Ejemplares similares